Apellis
Ophthalmology & Eye Clinics · Biologics & Biosimilars
Apellis is a global biopharmaceutical company that develops life-changing therapies It is hiring: 12 open roles, 0 of them posted in the last 30 days. Its stated pay is 52% above the market estimate for the same roles.
12Open roles
$200kMedian advertised pay$200k – $200k+52% vs market
54 daysTime to fillmedian of 11 closed rolesmarket: 33 days
Facts
as of Nov 13, 2026Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.
- Headquarters
- Cambridge, United States
- Employees
- 501-1000estimated range
- Open roles
- 12 in 2 citiesAlion job postings
- Website
- apellis.com
As of Nov 13, 2026, Alion lists 12 open roles at Apellis. Apellis is headquartered in Cambridge, United States. The median pay stated in its open roles is $200k, across 10 postings that state pay.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Hiring
All open roles →Hiring slowly: few roles were posted lately.
Marketing is the largest family, 75 of open roles.
17%Remote roles2 of 12
2Hiring offices
Can they hire you from United States?by your location
Likely
20 open roles are in your country: you apply locally, no move needed.
No posting offers visa sponsorship. Remote roles: 2.
Time to fillmedian days to close a role
Alion signals0-100
Demand24
Pay14
Your chance47
How badly they need people, whether they pay, how realistic getting in is.
Open roles over time−100%
Sep 21This week
Open roles a week: 18 then, 0 now
Where the openings areshare of open roles · trend
Degree asked
Bachelor's Degree 100%
Experience asked: 5.1 years on average, in 11 postings. 12 postings state a degree.
Benefits named in postingsshare of open roles
Contract type
Full-Time 12
Visa sponsorship: none statedRelocation: none stated
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family
Pays 52% above the market estimate for the same roles.
$200kMedianmarket estimate $131k
$200k – $200kTypical rangeUSD a year
$377kHighest paying roleExecutive Director, US EMPAVELI Brand Lead
Pay by levelmiddle half of stated pay, median marked · dashed: market median $131k
$0$63k$125k$188k$250k
Source: the pay stated in the company's postings, normalised to USD a year
Footprint
Hiring in 2 cities in 1 country.
2Cities
1Countries
CambridgeBusiest site
Loading the map
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| Cambridge United States | Headquarters | 2 | Marketing | 0% |
| Waltham United States | Regional office | 1 | Marketing | 0% |
Source: office addresses in postings and company registers
Tech stack
Technologies named in job postings at Apellis over the last 12 months, by layer, with the share of postings for each.
3Technologies in use
2Postings analysed
57/100Stack modernity
Sign in to see how your skills match this stackSign In
Source: the technologies named in the company's postings and on its site
Newsroom
top 3%Web presenceof 133.2M domains by links, Common Crawl
Dec 12, 20252025
News · seekingalpha.com
Jul 9, 20252025
News · YahooFinance
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the most promising stocks according to Wall Street analysts. On July 1, Apellis Pharmaceuticals announced a capped royalty pu…
Jun 30, 20252025
News · Nasdaq
Apellis secures $275 million upfront and potential $25 million in milestone payments from Sobi, enhancing financial strengths for kidney disease treatment.
Mar 5, 20252025
Nov 6, 20242024
News · The Motley Fool
Sales of the company's top commercialized product didn't meet expectations.
Oct 28, 20242024
Sources: the outlets named on each headline, each story once